U.S Market Study on Polycystic Ovarian Syndrome Treatment: Insulin Sensitizing Agents Drug Class Segment Projected to Reflect Highest Market Attractiveness Index Through 2024

Friday, April 21, 2017 Drug News
Email Print This Page Comment
Font : A-A+

LONDON, April 20, 2017 /PRNewswire/ -- The polycystic ovarian syndrome treatment market in the U.S is highly competitive

due to the presence of many local manufacturers and prevalence of low-cost generic drugs. However, manufacturers of brands in the country have strategically maintained their position in the market, owing to the unique value proposition and comparatively
lesser side effects. Download the full report: https://www.reportbuyer.com/product/4824284/The analysts of Persistence Market Research, while drafting a report on the U.S. polycystic ovarian syndrome treatment market titled "Polycystic Ovarian Syndrome Treatment Market: U.S. Industry Analysis and Forecast, 2016–2024," have observed that alliances with e-commerce partners and distribution agreements with strong local players is the key market strategy that is being followed by leading players in this market. While concentrating on target geographies, the analysts have further observed that the U.S. is a highly mature market where manufacturers are focused on developing advanced direct first line therapeutics for the treatment of polycystic ovarian syndrome with fewer side effects. Similarly, companies are also entering into strategic agreements with distributors and local players to increase the availability of their products in order to expand their market footprint. After a detailed study of the U.S. polycystic ovarian syndrome treatment market, the analysts have found that the U.S. shows a high prevalence rate of polycystic ovarian syndrome. This syndrome is associated with several other conditions such as type 2 diabetes mellitus, obesity, hirsutism and others. Also, women with polycystic ovarian syndrome are at a greater risk of developing type 2 diabetes mellitus. According to the report, the U.S. polycystic ovarian syndrome treatment market comprises several pharmaceutical drugs manufacturers based in the U.S. However, due to lack of FDA approved drugs for PCOS treatment, the market is dominated by small generic drugs manufacturers. These companies follow strong marketing and distribution strategies for facilitating a higher adoption of their polycystic ovarian syndrome treatment drugs across the country. Persistence Market Research provides key strategic recommendations for existing and new players in the market The U.S. polycystic ovarian syndrome treatment market report begins with an overview of the entire market. The report also underlines factors influencing the growth of the U.S. polycystic ovarian syndrome treatment market along with a detailing of the key trends, drivers, restraints, opportunities for market players and regulations. Impact analysis of key growth drivers and restraints based on the weighted average model along with important trends is included in the report to better equip clients with information and hidden insights. At the end of the report, Persistence Market Research provides key strategic recommendations for both existing and new players in the market to emerge sustainably profitable. A detailed analysis has been provided for each market segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market attractiveness index and BPS analysis. The next few sections provide a detailed analysis of every segment and sub-segment of the U.S. polycystic ovarian syndrome treatment market. The report further highlights the growth trends of the polycystic ovarian syndrome treatment market across the U.S and presents a market outlook for 2016–2024 – showcasing key trends contributing to the growth of the polycystic ovarian syndrome treatment market in the U.S. as well as an analysis of the extent to which drivers are influencing this market. The final section of the report includes detailed company profiles with company-specific long-term and short-term strategies, key offerings, and recent developments in the U.S polycystic ovarian syndrome treatment market. Market Segmentation By Drug Class - Oral Contraceptives - Insulin Sensitizing Agents - Anti-Depressants - Ornithine - Decarboxylase Inhibitors - Aromatase Inhibitors and SERMs - Diuretics By Distribution Channel - Hospital Pharmacies - Drug Stores / OTC - e-Commerce - Fertility Clinics Research Methodology The report considers 2015 as the base year and provides data for the forecast period 2016–2024. To deduce market size, the report considers various viewpoints based on extensive primary and secondary research. The report begins by sizing the current market – a key indicator of how the market is likely to grow during the forecast period. Download the full report: https://www.reportbuyer.com/product/4824284/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/us-market-study-on-polycystic-ovarian-syndrome-treatment-insulin-sensitizing-agents-drug-class-segment-projected-to-reflect-highest-market-attractiveness-index-through-2024-300443172.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook